Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study

[1] Gunton JE(2014)A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society Med J Aust 201 650-653

[2] Cheung NW(2007)The use of oral antidiabetic agents in primary care Aust Fam Physician 36 477-480

[3] Davis TM(2013)Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events Italian muticenter study J Am Geriatr Soc 61 1253-1261

[4] Zoungas S(2014)Medication safety and chronic kidney disease in older adults prescribted metformin: a cross-sectional analysis BMC Nephrol 15 86-1899

[5] Colagiuri S(2010)Metformin use and mortality among patients with diabetes and atherothrombosis Arch Intern Med 170 1892-200

[6] Weekes AJ(2017)Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review Ann Intern Med 166 191-2128

[7] Thomas MC(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-375

[8] Solini A(2017)Canagliflozin slows progression of renal function decline independently of glycemic effects J Am Soc Nephrol 28 368-334

[9] Penno G(2016)Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 375 323-41

[10] Bonora E(1976)Prediction of creatinine clearance from serum creatinine Nephron 16 31-68

[1] Gunton JE(2014)A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society Med J Aust 201 650-653

[2] Cheung NW(2007)The use of oral antidiabetic agents in primary care Aust Fam Physician 36 477-480

[3] Davis TM(2013)Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events Italian muticenter study J Am Geriatr Soc 61 1253-1261

[4] Zoungas S(2014)Medication safety and chronic kidney disease in older adults prescribted metformin: a cross-sectional analysis BMC Nephrol 15 86-1899

[5] Colagiuri S(2010)Metformin use and mortality among patients with diabetes and atherothrombosis Arch Intern Med 170 1892-200

[6] Weekes AJ(2017)Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review Ann Intern Med 166 191-2128

[7] Thomas MC(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-375

[8] Solini A(2017)Canagliflozin slows progression of renal function decline independently of glycemic effects J Am Soc Nephrol 28 368-334

[9] Penno G(2016)Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 375 323-41

[10] Bonora E(1976)Prediction of creatinine clearance from serum creatinine Nephron 16 31-68